Gastrointestinal toxicity of chemotherapeutic agents

Seminars in Oncology

Volumn 33, Issue 1, 2006, Pages 106-120

  Mitchell, Edith P ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; LOMUSTINE; MELPHALAN; METHOTREXATE; MITOMYCIN; MITOXANTRONE; OXALIPLATIN; PACLITAXEL; PENTOSTATIN; PROCARBAZINE; STREPTOZOCIN; UNINDEXED DRUG;

CANCER; CANCER CHEMOTHERAPY; CANDIDIASIS; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DISEASE EXACERBATION; ENTERITIS; ESOPHAGITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL INFECTION; GASTROINTESTINAL TOXICITY; HUMAN; MALABSORPTION; MALNUTRITION; MUCOSA INFLAMMATION; NAUSEA; NUTRITIONAL SUPPORT; PARENTERAL NUTRITION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION INJURY; REVIEW; SMALL INTESTINE OBSTRUCTION; VOMITING;

EID: 32244436980     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.12.001     Document Type: Article

References (231)

1. P.S. Schein, J.S. MacDonald, C. Waters Nutritional complications of cancer and its treatments Semin Oncol 2 1975 334 337
2. T. Ohnuma, J.F. Holland Nutritional consequences of cancer chemotherapy and immunotherapy Cancer Res 37 1977 2395 2406
3. E. Deschner, M. Lipkin Proliferation and differentiation of gastrointestinal cells in relation to therapy Med Clin North Am 55 1971 601 612
4. M. Lipkin, P. Sherlock, B. Bell Cell proliferation kinetics in the gastrointestinal tract of man.II Cell renewal in the stomach ileum, colon, rectum Gastroenterology 45 1963 721 772
5. M. Lipkin Cell replication in the gastrointestinal tract of man Gastroenterology 48 1965 616 662
6. M. Lipkin Proliferation and differentiation of gastrointestinal cells Physiol Rev 53 1973 891
7. L. Lenas, S.S. Steinberg, F.S. Phillips Cytoxic effects of 1-B-D arabino furnosyl-5-fluorocytosine and 1-B-D arabinofuranosylcytosine in proliferating tissues in mice Cancer Res 29 1970 1790 1798
8. R.C. Young, D. Goldberg, P.S. Schein Enhanced antitumor effect of cytosine arabinoside given in a schedule dictated by kinetic studies in vivo Biochem Pharmacol 22 1973 277 289
9. F.S. Phillips, S.S. Steinberg, H.S. Schwartz Hydroxyurea 1. Acute cell death in proliferating tissues in mice Cancer Res 27 1974 61 74
10. J.S. Tricer Morphologic alterations induced by methotrexate in the mucosa of human proximal intestine Gastroenterology 43 1962 407 424
11. H.S. Schwartz Actinomycin D effects on ridgeway sarcoma in mice Cancer Res 26 1966 1873 1879
12. E.P. Mitchell, A.S. Glicksman, P.S. Schein Acute and Late Effects of Cancer Therapy and Their Management in Medical Oncology 1993 McGraw-Hill New York, NY 345 369
13. C. Marran, D.C. Smith, D.A. Anderson Incidence of nausea and vomiting with cytotoxic chemotherapy A prospective randomized trial of antiemetics Br Med J 1 1979 1323
14. A. Coates, S. Abraham, S.B. Kaye On the receiving end. Patient perception of the side effect of cancer chemotherapy Eur J Cancer Clin Oncol 19 1983 203 208
15. C. Lindley Perception of chemotherapy side effects Cancer vs non cancer patients Cancer Pract 7 1999 59 65
16. D.J. Stewart Nausea and vomiting in cancer patients J. Kucharczyk D.J. Stewart A.D. Miller Nausea and Vomiting Recent Research and Clinical Advances 1991 CRC Press Boca Raton, FL 177
17. H.L. Borison, W.C. Wang Physiology and pharmacology of vomiting Pharmacol Rev 5 1953 193 230
18. H.L. Borison Area postrema: Chemoreceptors trigger zone for vomiting. Is that all? Life Sci 14 1974 1807 1817
19. R.A. Leslie Neuroactive substances in the dorsal vagal complex of the medulla oblongata Nucleus of the vagus Neurochem Int 7 1985 191 211
20. R.A. Leslie, Y. Shah, M. Thejomayan The neuropharmacology of emesis The role of receptors in neuro modulation of nausea and vomiting Can J Physiol Pharmacol 68 1990 279 288
21. M. Ostuka, K. Yoshioka Neurotransmitter functions of mammalian tachykinins Physiol Rev 73 1993 229 309
22. P.L.R. Andrews, R.J. Naylor, R.A. Joss Neuropharmacology of emesis and its relevance to antiemetic therapy Consensus and controversies Support Care Cancer 6 1998 197 203
23. J.R. Fozard Neuronal 5-HT receptors in the periphery Neuropharmacology 23 1984 1473 1486
24. M.B. Tyers 5-HT3 receptors Ann NY Acad Sci 600 1990 194 202
25. L.X. Cubeddu, I.S. Hoffman, N.T. Fuenmayor Efficacy of ondansetron (GR338032F) and the role of serotonin in cisplatin-induced nausea and vomiting N Engl J Med 322 1990 810 816
26. S.J. Gunning, R.M. Hagan, M.B. Tyers Cisplatin induces biochemical and histologic changes in the small intestine of the ferret Br J Pharmacol 90 1987 135 (abstr)
27. T. Endo, M. Minami, Y. Monami Emesis-related biochemical and histochemical changes induces by cisplatin in the ferret J Toxicol Sci 15 1990 235 244
28. D.O. Carpenter Neural mechanisms of emesis Can J Physiol Pharmacol 68 1990 230 236
29. P.J. Hornby Receptors and transmission in the brain-gut axis. II Excitatory amino acid receptors in the brain-gut axis Am J Physiolo Gastrointest Liver Physiol 280 2001 G1055 G1060
30. K.M.W. Pisters, M.G. Kris Treatment related nausea and vomiting A. Berger R.K. Partenoy D.E. Weissman Principles and Practice of Supportive Oncology 1998 Lippincott-Raven Philadelphia, PA 165 177
31. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer Prevention of chemotherapy and radiotherapy-induced emesis Results of the Perugia Concensus Conference Ann Oncol 9 1998 811 819
32. M.G. Kris, R.J. Gralla, R.A. Clark Incidence, course and severity of delayed nausea and vomiting following administration of high dose cisplatin J Clin Oncol 3 1985 1379 1384
33. G.B. Morrow Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients J Natl Cancer Inst 68 1982 585 588
34. P.M. Wilcox, J.H. Fetting, K.M. Nettersheim Anticipatory vomiting in women receiving cyclophosphamide, methotrexate and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma Cancer Treat Rep 66 1982 1601 1604
35. P.J. Hesketh, M.G. Kris, S.M. Grunberg Proposal for classifying the acute emetogenicity of cancer chemotherapy J Clin Oncol 15 1997 103 109
36. P.J. Hesketh Defining the emetogenicity of cancer chemotherapy regimens Relevance to clinical practice Oncologist 4 1999 191 196
37. P.J. Hesketh, S. Van Bell, M. Napro Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptors antagonists Eur J Cancer 39 2003 1074 1080
38. V. Cocquyt, S. Van Belle, R.R. Reinhardt Comparison of L-758,298 a jerodrug for the selective neurokinin-1 antagonist L-754, 030, with ondansetron for the prevention of cisplatin induced emesis Eur J Cancer 37 2001 835 842
39. D. Campos, J.R. Periera, R.R. Reinhardt Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone J Clin Oncol 19 2001 1759 1767
40. R. Tavorath, P.J. Hesketh Drug treatment of chemotherapy-induced delayed emesis Drugs 52 1996 639 648
41. D.H.G. Wilder-Smith, A. Borgeat, P. Chappuis Urinary serotonin metabolic excretion during cisplatin chemotherapy Cancer 72 1993 2239 2241
42. R.J. Jones, T. Muhonen, U.P. Karjalainen Urinary 5-hydroxyindolacetic acid (5-HIAA) excretion during multiple day high-dose chemotherapy Eur J Cancer 34 1988 196
43. R.J. Gralla, D. Osoba, M.G. Kris Recommendations for the use of antiemetics Evidence-based clinical practice guidelines J Clin Oncol 17 1999 2971 2994
44. L. Goedhals, J.-F. Heron, J.-P. Kleisbauer Control of delayed nausea and vomiting with granisetron plus dexamethasone alone in patients receiving highly emetogenic chemotherapy A double-blind, placebo-controlled comparative study Ann Oncol 9 1998 661 666
45. M.G. Kris, L.B. Tyson, R.J. Gralla Extrapyramidal reactions with high-dose metoclopramide N Engl J Med 309 1983 403 434
46. J.C. Allen, R.J. Gralla, L. Reilly Metoclopramide dose-related toxicity and preliminary antiemetic studies in children receiving chemotherapy J Clin Oncol 3 1985 1136 1141
47. P.J. Hesketh, P. Plagge, J.C. Bryson Single-dose ondansetron for prevention of acute cisplatin-induced emesis Analysis of efficacy and prognostic factors A.L. Branch L. Grelot A.D. Miller Mechanisms and Control of Emesis 1992 INSERM/John Libbey Eurotext London, UK 235 243
48. R.W. D'Acquisto, L.B. Tyson, R.J. Gralla The influence of chronic high alcohol intake on chemotherapy-induced nausea and vomiting) Proc Am Soc Clin Oncol 5 1986 257 (abstr 1006)
49. A.H. Berger, R.A. Clark-Snow Nausea and vomiting V.T. DeVita S. Hellman S.A. Rosenberg Cancer Principles and Practice of Oncology 2001 Lippincott Williams & Wilkins Philadelphia, PA 2869 2880
50. J.F. Holland E. Frei Cancer Medicine (ed 2) 1982 Lea & Febiger Philadelphia. PA 2332
51. P. Jacobsen, M. Andrykowski, W. Redd Nonpharmacologic factors in the development of posttreatment nausea with adjuvant chemotherapy for breast cancer Cancer 61 1988 379
52. M. Martin, E. Diaz-Rubio Emesis during pregnancy A new prognostic factor in chemotherapy-induced emesis Ann Oncol 1 1990 152
53. G.R. Morrow The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy Cancer 55 1985 2766
54. V. Guillem, E. Aranda, A. Carrato Previous history of emesis during pregnancy and motion sickness as risk factors for chemotherapy-induced emesis J Clin Oncol 2280 1999 590a (abstr)
55. S.M. Grunberg, M. Hansen, R.R. Denson Incidence of chemotherapy-induced nausea and emesis after modern antiemetics Cancer 100 2004 2261 2268
56. J. Latreille, J. Peter, D. Johnston Use of dexamethasone and granisetron in the control of delayed emesis for patients who received highly emetogenic chemotherapy J Clin Oncol 16 1998 1174 1178
57. R. desWit, S. Van den Bergtt, J. Burghouts Initial high antiemetic efficiency of granisetron with dexamethasone is not maintained over repeated cycles Br J Cancer 77 1998 1487 1491
58. J.M. Koeller, M.S. Aapro, R.J. Gralla Antiemetic guideline Creating a more practical treatment approach Support Care Cancer 10 2002 519 522
59. Multinational Association for Supportive Care in Cancer-Perugia International Cancer Conference VII-Concensus Conference on Antiemetic Therapy. Perugia 2004 antiemetic guidelines (online). http://www.mascc.org
60. National Comprehensive Cancer Network Clinical Guidelines and Outcomes Data in Oncology. www.nccn.org
61. W.D. Miner, G.J. Sanger, D.H. Turner Evidence that 5-hydroxtryptamines receptors mediate cytotoxic drug and radiation-evoked emesis Br J Cancer 56 1987 159 162
62. R.J. Gralla, L.M. Itri, S.E. Pisko Antiemetic efficacy of high-dose metoclopramide Randomized trials with placebo and prochlorperazine inpatients with chemotherapy-induced nausea and vomiting N Engl J Med 305 1981 905
63. L.H. Einhorn, C. Nagy, K. Werner Ondasetron A new antiemetic for patients receiving cisplatin chemotherapy J Clin Oncol 8 1990 731 735
64. M. Marty, P. Pouillart, S. Scholl Comparison of the 5-hydroxytryptamine (serotonin) antagonist ondansetron (GR38032F) with high dose metoclopramide in the control of cisplatin-induced emesis N Engl J Med 322 1990 816 821
65. P.H.M. DeMulder, C. Seynaeve, J.B. Vermorken Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting Ann Intern Med 113 1990 834 840
66. J. Hainesworth, W. Harvey, K. Pendergrass A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy J Clin Oncol 9 1991 721 728
67. B. Chevallier The control of acute cisplatin-induced emesis - A comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone Br J Cancer 68 1993 176 180
68. G.W. Sledge, L. Einhorn, C. Nagy Phase III double-blind comparison of intravenous ondansetron and metoclopramide as anti-emetic therapy for patients receiving multiple-day cisplatin-based chemotherapy Cancer 70 1992 2524 2528
69. The Granisetron Study Group The anti-emetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days J Cancer Res Clin Oncol 119 1993 555 559
70. B. Chevallier, P. Cappelaere, T. Splinter A double-blind, multicentre comparison of intravenous dolasetron mesylate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy Support Care Cancer 5 1997 22 30
71. D. Warr, A. Willan, S. Fine Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis J Natl Cancer Inst 83 1991 1169 1173
72. J. Bonneterre, B. Chavallier, R. Metz A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy J Clin Oncol 8 1990 1063 1069
73. N.W. Marschner, M. Adler, G.A. Nagel Double-blind randomized trial of the anti-emetic efficacy and safety of ondamsetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide Eur J Cancer 27 1991 1137 1140
74. A.L. Jones, A.S. Hill, M. Soukop Comparison of dexamethasone and oondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Lancet 338 1991 483 487
75. M. Marty A comparative study of the use of granisetron regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis Eur J Cancer 26 suppl 1 1990 S28 S32
76. M.G. Kris, R.J. Gralla, R.A. Clark Dose-ranging evaluation of the serotonin antagonist GRC507/75 (GR38032F) when used as an anti-emetic in patients receiving anticancer chemotherapy J Clin Oncol 6 1988 659 662
77. S.M. Grunberg, L.L. Stevenson, C.A. Russell Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting J Clin Oncol 7 1989 1137 1141
78. A. Riviere Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy Br J Cancer 69 1994 967 971
79. M.G. Kris, S.M. Grunberg, R.J. Gralla Dose-ranging evaluation of the serotonin antagonist dolasetron in patients receiving high-dose cisplatin J Clin Oncol 12 1994 1045 1049
80. P. Eisenberg, E.B. Rubinstein, L. Cohen Efficacy safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy A dose-ranging, clinical study Ann Oncol 15 2004 330 337
81. A.A. Fauser, B. Ducios, A. Chemaissam Therapeutic equivalence of single oral dose of dolasetron mesylate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy Eur J Cancer 32A 1996 1523 1529
82. S. Martoni, B. Angelelli, M. Guaraldi Granisetron versus ondansetron in the prevention of cisplatinum-induced emesis An open randomized cross-over study Proc Am Soc Clin Oncol 13 1994 431 (abstr)
83. R. Navari, D. Gandara, P. Hesketh Ondansetron compared with granisetron and ondanstron in the prophylaxis of cisplatin-induced emesis J Clin Oncol 13 1995 1242 1248
84. P. Ruff, W. Paska, L. Goedhals Ondansetron compared with granisetron in the prophylaxis pf cisplatin-induced emesis A multicenter double-blind, randomized, parallel-group study Oncology 41 1994 113 118
85. P. Hesketh, R. Navari, T. Grote Double-blind, randomized comparison of the anti-emetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer J Clin Oncol 14 1996 2242 2249
86. B. Audhuy, P. Cappelaere, M. Martin A double-blind, randomized comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesylate and granisetron in patients receiving high dose cisplatin chemotherapy Eur J Cancer 32A 1996 807 813
87. T. Bonneterre, B. Hecquet Granisetron (Iv) compared with ondansetron (Iv plus oral) in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy A cross-over study Bull Cancer 82 1995 1038 1043
88. A. Stewart, B. McQuade, J.D. Cronje Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in outpatients A multicenter, double-blind, double-dummy, randomized, paraellel-group study Oncology 52 1995 202 210
89. A. DelGiglio, H.P. Soares, C. Caparroz Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy induced nausea and vomiting Results of a meta-analysis of randomized controlled trials Cancer 89 2000 2301 2308
90. R. Gralla, M. Lichinitserm, G. Van der Vegts Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron Ann Oncol 14 2003 1570 1577
91. E.B. Rubenstein Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) Combined results of two phase III trials Proc Am Soc Clin Oncol 22 2003 729 (abstr 2932)
92. Aloxi (package insert) 2004 MGI Pharma, Inc Bloomington, MN
93. Zofran (package insert) 2001 GlaxoSmithKline Research Triangle Park, NC
94. Anzemet (package insert) 2000 Aventis Pharmaceuticals Bridgewater, NJ
95. Kytril (package insert) 2000 Roche Laboratories Inc, Nutley, NJ
96. E.H.F. Wong, R. Clark, E. Leung The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors in vitro Br J Pharmacol 114 1995 851 859
97. R.C. Miller, M. Galvan, M.W. Gittos Pharmacological properties of dolasetron, a potent and selective antagonist at 5HT3, receptors Drug Dev Res 28 1993 87 93
98. M.S. Aapro, A. Macciochi Palonosetron (PALO) is more effective than ondansetron/dolasetron (OND/DOL) in prevention chemotherapy induced nausea and vomiting (CINV) in elderly patients Combined results from 2 phase III trials Proc Am Soc Clin Oncol 23 2004 737 (abstr)
99. R.J. Gralla, L.M. Itri, S.E. Pisko Antiemetic efficacy of high-dose metoclopramide Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting N Engl J Med 305 1981 905 909
100. C. Basurto, F. Roila, M. Tonato Antiemetic activity of high dose metoclopramide combined with methylprednisolone versus metoclopramide alone in dacarbazine-treated cancer patients. A randomized double blind study of Italian Oncology Group for Clinical Research Am J Clin Oncol 12 1989 235
101. M.G. Kris, R.J. Gralla, R.A. Clark Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in conjunction with metoclopramide plus dexamethasone. A double blind, randomized trial Cancer 69 1987 1353
102. M.G. Kris, R.J. Gralla, L.B. Tyson Improved control of cisplatin induced emesis with high dose metoclopramide and with combinations of metoclopramide, dexamethasone and dipyhenhydramine. Results of consecutive trials in 255 patients Cancer 55 1985 527
103. F. Roila, V. De Angelis, F. Cognetti Ondansetron vs. granisetron, both combined with dexamethasone in the prevention of cisplatin induced emesis Proc Am Soc Clin Oncol 14 1995 523 (abstr)
104. P.H.M. DeMulder, C. Seynaeve, J.B. Vermorker Ondasetron compared with high dose metoclopramide in prophylaxis of acute and delayed cisplatin induced nausea and vomiting. A multicenter, randomized double blind, crossover study Ann Intern Med 113 1990 834
105. M.G. Kris, R.J. Gralla, L.B. Tyson Controlling delayed vomiting A double blind randomized trial comparing placebo, dexamethasone alone and metoclopramide plus dexamethasone in patients receiving cisplatin J Clin Oncol 7 1989 108
106. M.G. Kris, R.J. Gralla, L.B. Tyson Improved control of cisplatin induced emesis with high dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients Cancer 55 1985 527
107. T.M. Beck, P.J. Hesketh, S. Madajewicz Stratified, randomized, double blind comoparison of intravenous ondansetron administered as a multiple dose regimen versus two single dose regimens in the prevention of cisplatin-induced nausea and vomiting J Clin Oncol 10 1992 1969 1975
108. C. Seynaeve, J. Schuller, J. Buser Comparison of the antiemetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin induced emesis. A multicentre, double blind, randomized parallel group study Br J Cancer 66 1992 192 197
109. M. Marty, H. D'Allens A single daily dose of ondansetron is as effective as a continuous infusion in the prevention of cisplatin-induced nausea and vomiting Ann Oncol 1 suppl 1 1990 112 120
110. S. Chiarra, E. Campora, R. Lionetto Methylprednisolone for the control of CMF-induced emesis Am J Clin Oncol 10 1987 264 267
111. F. Roila, M. Tonato, C. Basurto Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with I.V. CMF Eur J Cancer Clin Oncol 23 1987 615 617 1987
112. N.E. Zaglama, S.L. Rosenblum, G.P. Sartiano Single, high-dose intravenous dexamethasone as an antiemetic in cancer chemotherapy Oncology 43 1986 27 32
113. P.A. Cassileth, E.J. Lusk, S. Torri Antiemetic efficacy of high-dose dexamethasone in induction therapy in acute nonlymphocytic leukemia Ann Intern Med 100 1984 701 702
114. C.N. Rittenberg, R.E.J. Gralla, L.A. Lettow New approaches in preventing delayed emesis altering the time of regimen initiation and use of combination therapy in a 1009 patient trial Proc Am Soc Clin Oncol 14 1995 526 (abstr)
115. F. Roila, M. Tonato, F. Cognetti Prevention of cisplatin-induced emesis a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone J Clin Oncol 9 1991 675
116. M.G. Kris, R.J. Gralla, L.B. Tyson Controlling delayed vomiting A double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone n patients receiving cisplatin J Clin Oncol 7 1989 108
117. R. Navari, D. Gandara, P. Hesketh Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis J Clin Oncol 13 1995 1242
118. M.G. Kris, S.M. Grunberg, R.J. Gralla Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high dose cisplatin J Clin Oncol 12 1994 1045
119. M.G. Kris, R.J. Gralla, R.A. Clark Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin J Natl Cancer Inst 81 1989 42
120. P.J. Jesketh, W.K. Murphy, R.P. Lester Gr38032F A novel compound effective in the prevention of acute cisplatin-induced emesis J Clin Oncol 7 1989 700
121. J. Hainsworth, W. Harvey, K. Pendergrass A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy J Clin Oncol 9 1991 721
122. H.G. Kaplan, C. Jofthagen Use of granisetron to prevent platinol induced nausea and vomiting Proc Am Soc Clin Oncol 10 1991 339 (abstr 1202)
123. H.J. Schrnoll The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes Eur J Cancer 25 suppl 1 1991 555
124. F. Roila, V. DeAngelis, F. Cognetti Ondansetron vs. granisetron, both combined with dexamethasone in the prevention of cisplatin-induced emesis Proc Am Soc Clin Oncol 14 1995 523 (abstr)
125. M.G. Kris, R.J. Gralla, R.A. Clark Dose ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as antiemetic in patients receiving cancer chemotherapy J Clin Oncol 6 1988 659
126. The Italian Group for Antiemetic Trials Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer N Engl J Med 332 1995 1
127. F. Roila, V. DeAngelis, F. Cognetti Ondansetron vs. granisetron, both combined with dexamethasone in the prevention of cisplatin-induced emesis Proc Am Soc Clin Oncol 14 1995 523 (abstr)
128. M.G. Kris, R.J. Gralla, R.A. Clark Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in conjunction with metoclopramide pluse dexamethasone. A double-blind, randomized trial Cancer 69 1987 1353
129. S.G. Dilly, C. Friedman, K. Yokom Contribution of dexamethasone to antiemetic control with granisetron is greatest in patients at high risk of emesis Proc Am Soc Clin Oncol 13 1994 436 (abstr)
130. C.L. Devane Substance P A new era, a new role Pharmacology 21 2001 1061 1069
131. 1) in the living human brain using positron emission tomography J Clin Psychiatry 63 suppl 11 2002 18 24
132. 1 receptor in the brain Pharmacology and putative functions Eur J Pharmacol 375 1999 51 60
133. 1 receptor antagonists in chemotheraphy-induced nausea and vomiting Support Care Cancer 9 2001 350 354
134. 1 receptor antagonists act centrally to inhibit emesis-induced by the chemotherapeutic agent cisplatin in ferrets Neuropharmacology 35 1996 1121 1129
135. V. Cocqreyt, S. VanBelle, R.R. Reinhardt Comparison of L-758, 298, a prodrug for the selective neurokinin-1 antagonist, L-574,030, with ondansetron for the prevention of cisplatin-induced emesis Eur J Cancer 37 2001 835 842
136. P.J. Hesketh, S. VanBelle, M.S. Aapro Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists Eur J Cancer 39 2003 1074 1080
137. R.M. Navari, R.R. Reinhardt, R.J. Gralla Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist N Engl J Med 340 1999 190 195
138. D. Campos, J. Pereira, R. Reinhardt MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone J Clin Oncol 19 2001 1759 1767
139. M.G. Kris, J.E. Radford, B.A. Pizzo Use of an NK-1 receptor antagonist to prevent delayed emesis after cisplatin J Natl Cancer Inst 89 1997 817 818
140. P.J. Hesketh, R.J. Gralla, R.T. Webb Randomized phase II study of the neurokinin-1-receptor antagonist CJ-11, 974 in the control of cisplatin-induced emesis J Clin Oncol 17 1999 338 343
141. S. VanBelle, M.R. Lichinitser, R.M. Navari Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. A randomized controlled trial Cancer 94 2002 3032 3041
142. Acute Leukemia Group B Acute lymphocytic leukemia in children JAMA 207 1969 923 928
143. E.J. Lamb, D.G. Morton, R.C. Byron Methotrexate therapy of choriocarcinoma and allied tumors Am J Obstet Gynecol 90 1964 317 327
144. I. Djerassi, S. Farber, E. Abir Continuous infusion of methotrexate in children with acute leukemia Cancer 20 1967 233 242
145. W.A. Bleyer The clinical pharmacology of methotrexate Cancer 41 1978 36 51
146. A. Dritschilo, A.J. Prio Clinical combinations of radiation and drugs in the management of tumors G.H. Sokol R.P. Maickel Radiation-Drug Interactions in the Treatment of Cancer 1980 Wiley New York, NY 180 186
147. R.C. Young, B.A. Chabner An in vivo method for determining differential effects of chemotherapy on targets tissues in animals and man. Correlation with plasma pharmacokinetics J Clin Invest 52 1973 92 (abstr)
148. B.A. Chabner, C.E. Myers, V.R. Oliverio Clinical pharmacology or anticancer drugs Semin Oncol 2 1977 165 191
149. B.A. Chabner, R.C. Young Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues J Clin Invest 52 1973 1804 1811
150. R.G. Stroller, S.A. Jacobs, J.C. Drake Pharmacokinetics of high-dose methotrexate (NSC-740) Cancer Chemother Rep 6 1975 19 24
151. D.H. Huffman, S.H. Wan, D.L. Azarnoff Pharmacokinetics of high-dose methotrexate (NSC 740) Clin Pharmacol Ther 14 1973 572 576
152. R.G. Stroller, K.R. Hande, S.A. Jacobs Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity N Engl J Med 297 1977 630 634
153. B.A. Chabner, D.G. Johns, J.R. Bertino Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity Nature 239 1972 395 397
154. W.H. Isacoff, C.M. Townsend, F.R. Eilber High dose methotrexate therapy of solid tumors Observations relating to clinical toxicity Med Pediatr Oncol 2 1976 319 325
155. W.A. Jacobs Methotrexate Clinical pharmacology; current status and therapeutic guidelines Cancer Treat Rev 4 1977 87 101
156. M. Leavitt, M.S. Masher, R.C. DeCanti Improved therapeutic index of methotrexate with "leucovorin rescue" Cancer Res 33 1973 1729 1734
157. S.A. Jacobs, W.A. Bleyer, B.A. Chabner Altered plasma pharmacokinetics of methotrexate administered intrathecally Lancet 1 1975 455 456
158. S.H. Wan, D.H. Huffman, D.L. Azarnoff Effects of route of administration and effusions on methotrexate pharmacokinetics Cancer Res 34 1974 3487 3491
159. F.S. Ansfield, G. Ramirez The clinical results of 5-flourouracil intrahepatic areterial infusion in 528 patients with metastic cancer to the liver I.M. Ariel Progress in Clinical Cancer vol 7 1978 Grune & Stratton New York, NY 201 206
160. P. Sherlock Acute gastritis from regional infusion of an antimetabolite Bull Gastrointest Endosc 9 1963 16 20
161. M. Innocenti Efficacy of Gelclair in reducing pain in palliative care patients with oral lesion Preliminary findings from an open pilot study J Pain Sympt Management 24 2003 456 457
162. J.S. Rubin, H. Osada, P.W. Finch Purification and characterization of newly identified growth factor specific for epithelial cells Proc Natl Acad Sci U S A 86 1989 802 806
163. J.S. Rubin, D.P. Botarro, M. Chedid Keratinocyte growth factor Cell Biol Int 19 1995 399 411
164. P.W. Finch, J.S. Rubin, T. Miki Human KGF is FGF-related with properties of a paracrine effector of epithelial growth Science 245 1989 752 755
165. R. Spielberger, P. Stiff, W. Bensinger Palifermin for oral mucositis after intensive therapy for hematologic cancers N Engl Med 351 2004 2590 2598
166. M.A. Wurth, X.J. Musacchila Mechlorethamine effects on intestinal absorption in vitro and on cell proliferation Am J Physiol 225 1973 73 80
167. R. Sobhon, C. Wanichanon, P. Stretarugsa Morphological changes induced by cyclophosphamide in crypt epithelium of the small intestine in mice Am J Anat 149 1977 563 584
168. M.T. Shaw, M.H. Spector, A.J. Ladman Effects of cancer, radiotherapy and cytotoxic drugs on intestinal structure and function Cancer Treat Rev 6 1979 141 151
169. A.L. Muggia, E. Wagman, S.S. Milles Response of the gastrointestinal tract of the mouse to 5-fluorouracil Am J Pathol 42 1963 407 414
170. A.C. Roche, J.C. Bognel, C. Boguel Correlation between the histological changes and glucose intestine absorption following a single dose of 5-fluorouracil Digestion 3 1970 195 212
171. R. Ecknauer, U. Lohrs The effect of a single dose of cyclophosphamide on the jejunum of specified pathogen fall and germ free rats Digestion 14 1976 269 280
172. M.D. Small, R.L. Cavanaugh, L. Gottlieb The effect of aminoprotein on the absorption of xylose from the rat small intestine Am J Dig Dis 4 1959 700 705
173. V.M.K. Venho Effect of methotrexate on drug adsorption from rat small intestine in situ and in vitro Acta Pharmacol Toxicol 38 1966 450 464
174. G. Hartwich, W. Domschke, F. Matzkies Disaccharidases of the intestinal mucosa of the rat with vincristine sulfate and ifosfamide Arzreisn Forsch 26 1976 350 352
175. T. Ohnuma, J.F. Holland, G. Nagel Effects of L-asparaginase in acute myelocytic leukemia JAMA 210 1969 1919 1921
176. T. Ohnuma, J.F. Holland, A. Frieman Biochemical and pharmacological studies with asparaginase in man Cancer Res 30 1970 2297 2305
177. S.W. Craft, H.E.M. Kay, D.N. Lawson Methotrexate-induced malabsorption in children with acute lymphoblastic leukemia Br Med J 2 1977 1511 1512
178. R.E. Slavin, M.A. Dias, R. Sarol Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols Cancer 42 1978 1747 1759
179. F.P. Smith, D. Kisner, L. Widerlite Chemotherapeutic alterations of small intestinal morphology and function A progress report Clin Gastroenterol 1 1979 203 207
180. F.P. Smith, D. Kisner, P.L. Schein Nutrition and cancer Prospects for clinical research Nutr Cancer 2 1980 34 39
181. I.W. Dymock, N. Mackay, V. Miller The effect of cancer on small intestinal function Br J Cancer 21 1967 505 511
182. H. Weiss, M. Walker, P. Wiernik Neurotoxicity of common used antineoplastic agents N Engl J Med 291 1974 75 81 127-133
183. S. Rosenthal, S. Kaufman Vincristine neurotoxicity Ann Intern Med 80 1975 733 737
184. J.F. Holland, C. Scharlau, S. Gailani Vincristine treatment of advances cancer a cooperative study of 392 cases Cancer Res 33 1973 1258 1264
185. S.G. Sandler, W. Tobin, E.S. Henderson Vincristine induced neuropathy A clinical study of fifty leukemia patients Neurology (Minn) 19 1969 367 374
186. P. Sherlock Effect of cancer treatment on nutrition and gastrointestinal function Clin Bull 9 1979 136 145
187. J. Killen, E.P. Mitchell, P.V. Woolley Phase II studies of methylglyoxal-bis-guanylhydrazone Cancer 50 1982 1258 1261
188. A.B. Benson, J.A. Ajani, R.B. Catalano Recommended guidelines for the treatment of cancer treatment-induced diarrhea J Clin Oncol 22 2004 2918 2926
189. P. Eras, M.J. Goldstein, P. Sherlock Candida infections of the gastrointestinal tract Medicine 51 1972 367 379
190. G.P.L. Bodey Fungal infections complicating acute leukemia J Chronic Dis 19 1966 667 687
191. S.A. Kaufman, S. Scheff, G. Levine Esophageal moniliasis Radiology 75 1960 726 732
192. A.M. Lewicki, J.P. Moore Esophageal moniliasis A review of common and less frequent characteristics Am J Roentgenol Radium Ther Nucl Med 125 1975 218 225
193. E. Svejgaard Miconazole in the treatment of candidiasis of the digestive tract Acta Dermatovnor 56 1976 303 306
194. G. Medoff, W.E. Dismukes, R.H. Meade III A new therapeutic approach to candida infection Arch Intern Med 130 1972 241 243
195. A.N. Ehrlich, G. Stalder, W. Gellew The gastrointestinal manifestations of malignant lymphoma Gastroenterology 54 1968 1115 1121
196. W.H. Hartman, P. Sherlock Gastroduodenal metastases from carcinoma of the breast an adrenal steroid-induced phenomenon Cancer 14 1961 426 431
197. S.S. Donaldson, J.R. Castro, J.R. Wilbur Rhabdomyosarcoma of head and neck in children Combination treatment by surgery, irradiation and chemotherapy Cancer 31 1973 26 35
198. S.S. Donaldson, S. Jundt, C. Ricour Radiation enteritis in children A retrospective review, clinicopathologic correlation and dietary management Cancer 35 1975 1167 1178
199. S.S. Donaldson, R.A. Lenon Alteration of nutritional status The impact of chemotherapy and radiation therapy Cancer 43 1979 2036 2052
200. S.S. Donaldson Nutritional consequences of radiotherapy Cancer Res 37 1977 2407 2413
201. J.R. Cassady, U. Tefft, R.M. Filler Consideration in the radiation therapy of Wilms' tumor Cancer 32 1973 598 608
202. M.A. Bagshaw, R.L.S. Doggett A clinical study of radiosensitization D. Front Radiation Therapy Oncology vol 4 1969 Skarger New York, NY 164 173
203. C.F. Von Essen, M.M. Kligerman, P.L. Calabresi Radiation and 5-flourouracil. A controlled clinical study Radiology 81 1963 1018 1027
204. T.L. Phillips, M.D. Wharam, L.W. Margolis Modification of radiation injury to normal tissues by chemotherapeutic agents Cancer 35 1975 1678 1684
205. H. Lerner, M. Beckloff, C. Goodwin Concomitant hydroxyurea and radiotherapy in the management of 60 patients with head and neck cancer Am Surg 35 1969 525 534
206. F.S. Phillips, S.S. Sternberg, H.S. Schwartz Hydroxyurea 1. Acute cell death in proliferating tissues in mice Cancer Res 27 1967 61 74
207. T. Hall, M. Diderick, T. Chalmers A clinical pharmacologic study of chemotherapy and x-ray therapy in lung cancer Am J Med 43 1967 186 193
208. J.P. Concannon, M.H. Dalbow, R.F. Hageman Radiation and actinomycin D mortality studies in C'57 BL/6 mice Cancer 32 1973 553 561
209. J.P. Concannon, R.E. Summers, J. King Enhancement of x-ray effect on the small intestinal epithelium of dogs by actinomycin Am J Roentgenol 105 1969 126 136
210. J.E. Byfield, W.G. Watring, S.R. Lemkin Adriamycin A useful adjuvant drug for combination with radiation therapy Proc Am Assoc Cancer Res 16 1975 253 (abstr)
211. E.G. Mayer, C. Paulter, S.L. Aristzapal Complications of irradiation related to apparent drug potentiation by adriamycin Int J Radiat Oncol Biol Phys 1 1976 1179 1188
212. F.A. Greco, H.D. Brereton, H. Kent Adriamycin and enhanced radiation reaction in normal esophagus and skin Ann Intern Med 85 1976 294 298
213. H.D. Brereton, C.H. Kent, R.E.L. Johnson Chemotherapy and radiation therapy for small cell cancer of the lung A remedy for past therapeutic failure F. Muggia M. Rozencweig Lung Cancer Progress in Therapeutic Research 1979 Raven New York, NY 579 586
214. C.G. Moertel, D.S. Childs, R.J. Reitemeir Combined 5-flourouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer Lancet 2 1969 865 867
215. R.C. Landgren, D.H. Hussey, H.T. Barkley Split-course irradiation plus hydroxyurea in inoperable bronchogenic carcinoma. A randomized study of 53 patients Cancer 34 1974 1598 1601
216. R.C. Landgren, D.H. Hussy, M. Samuels A randomized study comparing irradiation alone to irradiation plus procarbazine in inoperable bronchogenic carcinoma Radiology 108 1973 403 406
217. P. Coy A randomized study of irradiation and vinblastine in lung cancer Cancer 26 1970 803 807
218. S.S. Donaldson, J.M. Glick, S.R. Wilbur Adriamycin activating a recall phenomenon after radiation therapy Ann Intern Med 81 1974 407 408
219. W.G. Watring, J.E. Byfield, L.D. Lagasse Combination of Adriamycin and radiation therapy in gynecologic cancers Gynecol Oncol 2 1974 518 526
220. B.W. Fox, L.G. Lagtha Radiation damage and repair phenomenon Br Med Bull 29 1973 16 22
221. A. Dritschilo, A.J. Piro, J.A. Bell Interaction between radiation and drug damage in mammalian cells. III: The effect of Adriamycin and actinomycin D on the repair of potentially lethal radiation damage Int J Radiat Biol Phys 35 1979 549 560
222. T.L. Phillips, K. Fu Quantification of combined radiation therapy and chemotherapy effects on normal tissue Cancer 37 1976 1186 1200
223. E.A. Sonchon, E.M. Copeland, P. Watson Intravenous hyperalimentation as an adjunct to cancer chemotherapy with fluorouracil Surg Res 18 1975 451 454
224. E.M. Copeland III, B.V. MacFayden Jr, S.J. Dudrick Intravenous hyperalimentation in cancer patients J Surg Res 16 1974 241 247
225. E.M. Copeland III, B.V. MacFayden Jr, W.S. MacComb Intravenous hyperalimentation with head and neck cancer Cancer 35 1975 606 611
226. E.M. Copeland III, B.V. MacFayden Jr, V. Lanzotti Intravenous hyperalimentation as an adjunct to cancer chemotherapy Am J Surg 129 1975 167 173
227. H.I.V. Lanzo, E.M. Copeland, S. George Cancer chemotherapeutic response and intravenous hyperalimentation Cancer Treat Rep 59 1975 437 439
228. E.M. Copeland III, B.V. MacFayden Jr, W.S. MacCombs Intravenous hyperalimentation as an adjunct to cancer treatment in the adult Cancer Res 37 1977 2451 2456
229. R.M. Filler, N. Jaffe, J.R. Cassady Parenteral nutritional support in children with cancer Cancer 39 1977 2665 2669
230. G. Schwartz, H. Green, M. Bendon Combined parenteral hyperalimentation and chemotherapy in the treatment of disseminated solid tumors Am J Surg 121 1977 169 173
231. G. Bounous, J.M. Gentiles, J. Hugon Elemental diet in the intestinal lesion produced by 5-fluorouracil in man Can J Surg 14 1971 312 324